JP2003516936A - アジュバント化遺伝子ワクチン - Google Patents

アジュバント化遺伝子ワクチン

Info

Publication number
JP2003516936A
JP2003516936A JP2001534412A JP2001534412A JP2003516936A JP 2003516936 A JP2003516936 A JP 2003516936A JP 2001534412 A JP2001534412 A JP 2001534412A JP 2001534412 A JP2001534412 A JP 2001534412A JP 2003516936 A JP2003516936 A JP 2003516936A
Authority
JP
Japan
Prior art keywords
adjuvant
composition
antigen
nucleic acid
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001534412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516936A5 (enExample
Inventor
ジョエル アール． ヘイネス，
ジョージ ウィデラ，
ジェイムズ ティー． フラー，
ティモシー シフリー，
デボラ フラー，
メアリー ウ，
Original Assignee
パウダージェクト ヴァクシンズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パウダージェクト ヴァクシンズ，インコーポレイテッド filed Critical パウダージェクト ヴァクシンズ，インコーポレイテッド
Publication of JP2003516936A publication Critical patent/JP2003516936A/ja
Publication of JP2003516936A5 publication Critical patent/JP2003516936A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2001534412A 1999-11-03 1999-11-03 アジュバント化遺伝子ワクチン Pending JP2003516936A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/025854 WO2001032208A1 (en) 1999-11-03 1999-11-03 Adjuvanted genetic vaccines

Publications (2)

Publication Number Publication Date
JP2003516936A true JP2003516936A (ja) 2003-05-20
JP2003516936A5 JP2003516936A5 (enExample) 2006-12-28

Family

ID=22273970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534412A Pending JP2003516936A (ja) 1999-11-03 1999-11-03 アジュバント化遺伝子ワクチン

Country Status (14)

Country Link
EP (1) EP1227840B1 (enExample)
JP (1) JP2003516936A (enExample)
CN (1) CN100333794C (enExample)
AT (1) ATE374622T1 (enExample)
AU (1) AU780448C (enExample)
CA (1) CA2389686A1 (enExample)
CY (1) CY1107845T1 (enExample)
DE (1) DE69937258T2 (enExample)
DK (1) DK1227840T3 (enExample)
ES (2) ES2294864T3 (enExample)
IL (2) IL149415A0 (enExample)
NZ (1) NZ518766A (enExample)
PT (2) PT1227840E (enExample)
WO (1) WO2001032208A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460945T1 (de) * 1999-11-03 2010-04-15 Powderject Vaccines Inc Genetische adjuvanz-impfstoffe
BR0209854A (pt) * 2001-05-18 2004-06-08 Powderject Vaccines Inc Molécula de ácido nucléico recombinante, cassete de expressão, vetor, polipeptìdeo, composição de vacina, dispositivo de aceleração de partìcula, e, método para gerar uma resposta imune celular em um indivìduo
US7566478B2 (en) 2001-07-25 2009-07-28 Nantero, Inc. Methods of making carbon nanotube films, layers, fabrics, ribbons, elements and articles
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
US11207241B2 (en) 2013-03-15 2021-12-28 Phd Preventative Health Care And Diagnostics, Inc. Prefilled medication device, method of making and using the same
WO2020252263A1 (en) 2019-06-12 2020-12-17 Wisconsin Alumni Research Foundation Novel adjuvant for animal and human vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026718A1 (en) * 1994-04-01 1995-10-12 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1997028820A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Biologicals S.A. Vaccines against varicella zoster virus gene 63 product
WO1998035562A1 (en) * 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
AU6897098A (en) * 1997-04-14 1998-11-11 University Of Massachusetts Medical Center Saponin adjuvants in combination with dna vaccination
CN1285753A (zh) * 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
CU22740A1 (es) * 1998-09-07 2002-02-28 Ct Ingenieria Genetica Biotech Formulación de ácidos nucleicos y acemanano

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026718A1 (en) * 1994-04-01 1995-10-12 Apollon, Inc. Compositions and methods for delivery of genetic material
JPH09511146A (ja) * 1994-04-01 1997-11-11 アポロン・インコーポレーテッド 遺伝物質の配達に関する組成物および方法
WO1997028820A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Biologicals S.A. Vaccines against varicella zoster virus gene 63 product
WO1998035562A1 (en) * 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5002001001, ＳＡＳＡＫＩ， Ｓ．， ｅｔ ａｌ．, ＡＮＴＩＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, 199809, Ｖ１８ Ｎ５Ｄ, Ｐ３９０７−３９１６ *
JPN5002001002, ＳＡＳＡＫＩ， Ｓ．， ｅｔ ａｌ．, ＩＮＦＥＣＴＩＯＮ ＡＮＤ ＩＭＭＵＮＩＴＹ, 199709, Ｖ９ Ｎ６５, Ｐ３５２０−３５２８ *
JPN6009068336, ＨＡＹＮＥＳ， Ｊ．Ｒ．, "ＧＥＮＥＴＩＣ ＶＡＣＣＩＮＥＳ", ＩＮＦＥＣＴＩＯＵＳ ＤＩＳＥＡＳＥ ＣＬＩＮＩＣＳ ＯＦ ＮＯＲＴＨ ＡＭＥＲＩＣＡ, 199903, Ｖｏｌ．１３， Ｎｏ．１, ｐ．１１−２６ *
JPN6009068338, ＰＵＴＫＯＮＥＮ， Ｐ．， ｅｔ ａｌ．, "Ｉｍｍｕｎｅ Ｒｅｓｐｏｎｓｅｓ ｂｕｔ Ｎｏ Ｐｒｏｔｅｃｔｉｏｎ ａｇａｉｎｓｔ ＳＨＩＶ ｂｙ Ｇｅｎｅ−Ｇｕｎ Ｄｅｌｉｖｅｒｙ ｏｆ ＨＩＶ−１ ＤＮＡ Ｆｏｌｌｏｗｅｄ ｂｙ Ｒｅｃｏｍｂ", ＶＩＲＯＬＯＧＹ, 19981025, Ｖｏｌ．２５０， Ｎｏ．２, ｐ．２９３−３０１ *
JPN6009068339, ＣＨＥＮ， Ｚ．， ｅｔ ａｌ．, "Ｐｒｏｔｅｃｔｉｏｎ ａｎｄ ａｎｔｉｂｏｄｙ ｒｅｓｐｏｎｓｅｓ ｉｎ ｄｉｆｆｅｒｅｎｔ ｓｔｒａｉｎｓ ｏｆ ｍｏｕｓｅ ｉｍｍｕｎｉｚｅｄ ｗｉｔｈ ｐｌａｓｍｉｄ ＤＮＡｓ ｅｎｃｏｄｉｎｇ", Ｊｏｕｒｎａｌ ｏｆ Ｇｅｎｅｒａｌ ｖｉｒｏｌｏｇｙ, 199910, Ｖｏｌ．８０， Ｎｏ．１０, ｐ．２５５９−２５６４ *
JPN6009068341, ＬＥＩＴＮＥＲ， Ｗ．Ｗ．， ｅｔ ａｌ．, "Ｉｍｍｕｎｅ Ｒｅｓｐｏｎｓｅｓ Ｉｎｄｕｃｅｄ ｂｙ Ｉｎｔｒａｍｕｓｃｕｌａｒ ｏｒ Ｇｅｎｅ Ｇｕｎ Ｉｎｊｅｃｔｉｏｎ ｏｆ Ｐｒｏｔｅｃｔｉｖｅ Ｄｅｏｘｙｒｉｂｏｎｕｃｌｅｉｃ Ａｃｉｄ", Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ, 19971215, Ｖｏｌ．１５９， Ｎｏ．１２, ｐ．６１１２−６１１９ *

Also Published As

Publication number Publication date
CA2389686A1 (en) 2001-05-10
PT1227840E (pt) 2008-01-09
ES2340617T3 (es) 2010-06-07
ATE374622T1 (de) 2007-10-15
CN1426309A (zh) 2003-06-25
CY1107845T1 (el) 2013-06-19
CN100333794C (zh) 2007-08-29
PT1913957E (pt) 2010-05-05
ES2294864T3 (es) 2008-04-01
AU1339900A (en) 2001-05-14
WO2001032208A1 (en) 2001-05-10
AU780448B2 (en) 2005-03-24
EP1227840B1 (en) 2007-10-03
DE69937258T2 (de) 2008-07-03
AU780448C (en) 2006-02-23
IL149415A (en) 2008-11-03
IL149415A0 (en) 2002-11-10
DE69937258D1 (de) 2007-11-15
NZ518766A (en) 2005-07-29
DK1227840T3 (da) 2008-02-04
EP1227840A1 (en) 2002-08-07

Similar Documents

Publication Publication Date Title
US7699801B2 (en) Advanced genetic vaccines
Schlosser et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses
SK282920B6 (sk) Prostriedok na indukciu cytotoxickej T-lymfocytovej odpovede a jeho použitie
JP2000503853A (ja) 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
AU756828B2 (en) Transdermal delivery of particulate vaccine compositions
US10172936B2 (en) Peptide particle formulation
US20070026015A1 (en) Method
JP4221289B2 (ja) 核酸アジュバント
JP2003528818A (ja) 皮膚経路を介したワクチン接種による粘膜免疫の誘導
EP1227840B1 (en) Adjuvanted genetic vaccines
AU2001297988A1 (en) Nucleic acid adjuvants
EP1913957B1 (en) Adjuvanted genetic vaccines
AU2012229234B2 (en) Vaccine formulation of mannose coated peptide particles
KR100204732B1 (ko) 세포성 면역반응을 유도하는 비이형 간염 백신 및 이의 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061030

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061030

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20061030

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080708

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100527

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100913